Zobrazeno 1 - 10
of 621
pro vyhledávání: '"Joon Oh PARK"'
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
Autor:
Joon Oh Park, Yin-Hsun Feng, Wu-Chou Su, Do-Youn Oh, Bhumsuk Keam, Lin Shen, Sang-We Kim, Xiufeng Liu, Huimin Liao, Min Qing, Chong Zhang, Jiaqi Qian, Xiaodan Tang, Peng Li, Spyros Triantos, Hussein Sweiti
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background FGFR genomic aberrations occur in approximately 5–10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR-altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecologica
Externí odkaz:
https://doaj.org/article/46cf37a8f4c5475998d9519b116a314e
Autor:
Keisuke Okuno, Shuichi Watanabe, Hoon Hur, Jeeyun Lee, Joon Oh Park, Masanori Tokunaga, Minoru Tanabe, Yusuke Kinugasa, Ajay Goel
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 7, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/2638aa8468b641199d2db74163cea5f5
Autor:
Kangpyo Kim, Hee Chul Park, Jeong Il Yu, Joon Oh Park, Jung Yong Hong, Kyu Taek Lee, Kwang Hyuck Lee, Jong Kyun Lee, Joo Kyung Park, Jin Seok Heo, Sang Hyun Shin, Ji Hye Min, Kyunga Kim, In Woong Han
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 45, Iss , Pp 100732- (2024)
Background: To evaluate the efficacy and optimal timing of local treatment in patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) treated with upfront FOLFIRINOX. Method: Between 2015 and 2020, 258 patients with panc
Externí odkaz:
https://doaj.org/article/b61aeb37243a40a3a98e1d0a3242d69d
Autor:
Bhumsuk Keam, Chan-Young Ock, Do-Youn Oh, Seung-Tae Kim, Keun-Wook Lee, Sun Young Rha, Changhoon Yoo, John Park, Min Hwan Kim, Sehyun Kim, Dhanusha Sabanathan, Joon Oh Park, Napa Parinyanitikul, Kyu Pyo Kim, Jaebong Yoon, Hyelim Lim, Sangheon Lee, Wooick Jang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/5009271548a74b489eadc49eed000e3d
Autor:
Ji Eun Kim, Hyemin Kim, Binnari Kim, Hye Gyo Chung, Hwe Hoon Chung, Kyoung Mee Kim, Seong Hyun Kim, Woo Kyoung Jeong, Young Kon Kim, Ji Hye Min, Jin Seok Heo, In Woong Han, Sang Hyun Shin, Hee Chul Park, Jeong Il Yu, Joon Oh Park, Seung Tae Kim, Jung Yong Hong, Se‐Hoon Lee, Kwang Hyuck Lee, Jong Kyun Lee, Kyu Taek Lee, Kee‐Taek Jang, Joo Kyung Park
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 7748-7761 (2023)
Abstract Pancreaticobiliary tract cancer has a poor prognosis with unmet needs in a new target treatment. Some studies have reported that an enhancement of T‐cell immunity is associated with a good prognosis. The aim of this study is to investigate
Externí odkaz:
https://doaj.org/article/9071de54d0284ff989a250770586c1f5
Autor:
Eunji Hong, Wojciech Barczak, Sujin Park, Jin Sun Heo, Akira Ooshima, Shonagh Munro, Chang Pyo Hong, Jinah Park, Haein An, Joon Oh Park, Seok Hee Park, Nick B. La Thangue, Seong-Jin Kim
Publikováno v:
Cell Death and Disease, Vol 14, Iss 2, Pp 1-9 (2023)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is the most lethal type of cancer and the third leading cause of cancer death with the lowest 5-year survival rate. Heterogeneity, difficulty in diagnosis, and rapid metastatic progression are the caus
Externí odkaz:
https://doaj.org/article/85a923602ad6487c84f3e62535105d87
Autor:
Sun Young Jeong, Jung Yong Hong, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Jae Yeon Jang, Youngkyung Jeon, Seung Tae Kim
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: With a 15% incidence, KRAS is one of the most common mutations in biliary tract cancer (BTC) and is a poor prognostic factor. Immune checkpoint inhibitors (ICIs) as salvage therapy have modest activity in BTC. Objectives: There are limite
Externí odkaz:
https://doaj.org/article/0bb07600025f4925b23ab1ee1ce2d3fc
Autor:
Sung Hee Lim, Jaeyun Jung, Jung Young Hong, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Kyoung-Mee Kim, Jeeyun Lee
Publikováno v:
Biomedicines, Vol 11, Iss 12, p 3264 (2023)
Purpose: Therapeutic targeting of RAF1 is a promising cancer treatment, but the relationship between clinical features and RAF1 aberrations in terms of the MAPK signaling pathway is poorly understood in various solid tumors. Methods: Between October
Externí odkaz:
https://doaj.org/article/9802d46e123e4ee38b6fc134ba6d3c77
Autor:
In-Seob Lee, Zhongxu Zhu, Jeeyun Lee, Joon Oh Park, Xiwei Wu, Tiffany Ong, Sierra Min Li, Xin Wang, Joseph Chao, Ajay Goel
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-5 (2022)
Externí odkaz:
https://doaj.org/article/cec93c77b94e4008b5d75a9eed986bad
Autor:
Jihoon Ko, Jaeyun Jung, Seung Tae Kim, Jung Yong Hong, Sehhoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Soomin Ahn, Kyoung-Mee Kim, Won Ki Kang, Jeeyun Lee
Publikováno v:
Pathology and Oncology Research, Vol 28 (2022)
Background: To aid in oncology drug development, we investigated MET proto-oncogene receptor tyrosine kinase gene aberrations in 2,239 oncology patients who underwent next-generation sequencing (NGS) in clinical practice.Materials and methods: From N
Externí odkaz:
https://doaj.org/article/8a77c40a11f6496c8c69c8e9d5711c38